BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26559839)

  • 1. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
    Herrman M; Mühe J; Quink C; Wang F
    J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.
    Sashihara J; Hoshino Y; Bowman JJ; Krogmann T; Burbelo PD; Coffield VM; Kamrud K; Cohen JI
    PLoS Pathog; 2011 Oct; 7(10):e1002308. PubMed ID: 22028652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-human Primate Lymphocryptoviruses: Past, Present, and Future.
    Mühe J; Wang F
    Curr Top Microbiol Immunol; 2015; 391():385-405. PubMed ID: 26428382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning of the Epstein-Barr virus-related rhesus lymphocryptovirus as a bacterial artificial chromosome: a loss-of-function mutation of the rhBARF1 immune evasion gene.
    Ohashi M; Orlova N; Quink C; Wang F
    J Virol; 2011 Feb; 85(3):1330-9. PubMed ID: 21084476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model.
    Mühe J; Aye PP; Quink C; Eng JY; Engelman K; Reimann KA; Wang F
    Cell Rep Med; 2021 Jul; 2(7):100352. PubMed ID: 34337567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue.
    Fogg MH; Kaur A; Cho YG; Wang F
    J Virol; 2005 Oct; 79(20):12681-91. PubMed ID: 16188971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.
    Orlova N; Fogg MH; Carville A; Wang F
    Clin Vaccine Immunol; 2011 Sep; 18(9):1427-34. PubMed ID: 21734064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.
    Leskowitz R; Fogg MH; Zhou XY; Kaur A; Silveira EL; Villinger F; Lieberman PM; Wang F; Ertl HC
    J Virol; 2014 May; 88(9):4721-35. PubMed ID: 24522914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.
    Ohashi M; Fogg MH; Orlova N; Quink C; Wang F
    PLoS Pathog; 2012 Dec; 8(12):e1003095. PubMed ID: 23300447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhesus lymphocryptovirus infection during the progression of SAIDS and SAIDS-associated lymphoma in the rhesus macaque.
    Habis A; Baskin G; Simpson L; Fortgang I; Murphey-Corb M; Levy LS
    AIDS Res Hum Retroviruses; 2000 Jan; 16(2):163-71. PubMed ID: 10659055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques.
    Fogg MH; Garry D; Awad A; Wang F; Kaur A
    J Immunol; 2006 Mar; 176(6):3391-401. PubMed ID: 16517707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
    Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
    Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
    Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
    Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus.
    Singh S; Homad LJ; Akins NR; Stoffers CM; Lackhar S; Malhi H; Wan YH; Rawlings DJ; McGuire AT
    Cell Rep Med; 2020 Jun; 1(3):. PubMed ID: 32724901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques.
    Leskowitz RM; Zhou XY; Villinger F; Fogg MH; Kaur A; Lieberman PM; Wang F; Ertl HC
    J Virol; 2013 Aug; 87(15):8351-62. PubMed ID: 23698300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular evidence for rhesus lymphocryptovirus infection of epithelial cells in immunosuppressed rhesus macaques.
    Kutok JL; Klumpp S; Simon M; MacKey JJ; Nguyen V; Middeldorp JM; Aster JC; Wang F
    J Virol; 2004 Apr; 78(7):3455-61. PubMed ID: 15016868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
    J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.